During the last three months, 4 analysts shared their evaluations of Haemonetics (NYSE:HAE), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 2 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $110.5, a high estimate of $125.00, and a low estimate of $105.00. Witnessing a positive shift, the current average has risen by 2.0% from the previous average price target of $108.33.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Haemonetics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Turkaly | JMP Securities | Raises | Market Outperform | $125.00 | $115.00 |
| Michael Petusky | Barrington Research | Raises | Outperform | $107.00 | $105.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $105.00 | $105.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $105.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Haemonetics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Haemonetics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Haemonetics's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into Haemonetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Haemonetics analyst ratings.
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Haemonetics's Economic Impact: An Analysis
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Haemonetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.14% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Haemonetics's ROE stands out, surpassing industry averages. With an impressive ROE of 3.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Haemonetics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.48% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Haemonetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.92, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.